These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1500160)

  • 1. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.
    Schneerson R; Levi L; Robbins JB; Bryla DM; Schiffman G; Lagergard T
    Infect Immun; 1992 Sep; 60(9):3528-32. PubMed ID: 1500160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
    Marsili I; Pizza M; Giovannoni F; Volpini G; Bartalini M; Olivieri R; Rappuoli R; Nencioni L
    Infect Immun; 1992 Mar; 60(3):1150-5. PubMed ID: 1541530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide.
    Peeters CC; Tenbergen-Meekes AM; Poolman JT; Zegers BJ; Rijkers GT
    Vaccine; 1992; 10(12):833-40. PubMed ID: 1455909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
    Cropley I; Douce G; Roberts M; Chatfield S; Pizza M; Marsili I; Rappuoli R; Dougan G
    Vaccine; 1995 Dec; 13(17):1643-8. PubMed ID: 8719514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit.
    Walker MJ; Rohde M; Timmis KN; Guzmán CA
    Infect Immun; 1992 Oct; 60(10):4260-8. PubMed ID: 1398937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.
    Fattom A; Lue C; Szu SC; Mestecky J; Schiffman G; Bryla D; Vann WF; Watson D; Kimzey LM; Robbins JB
    Infect Immun; 1990 Jul; 58(7):2309-12. PubMed ID: 2365462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1347-51. PubMed ID: 2304902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.
    Arciniega JL; Shahin RD; Burnette WN; Bartley TD; Whiteley DW; Mar VL; Burns DL
    Infect Immun; 1991 Oct; 59(10):3407-10. PubMed ID: 1894354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.
    Alonso de Velasco E; Verheul AF; van Steijn AM; Dekker HA; Feldman RG; Fernández IM; Kamerling JP; Vliegenthart JF; Verhoef J; Snippe H
    Infect Immun; 1994 Mar; 62(3):799-808. PubMed ID: 7509318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.
    Fattom A; Schneerson R; Szu SC; Vann WF; Shiloach J; Karakawa WW; Robbins JB
    Infect Immun; 1990 Jul; 58(7):2367-74. PubMed ID: 2114365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.
    Chu C; Schneerson R; Robbins JB; Rastogi SC
    Infect Immun; 1983 Apr; 40(1):245-56. PubMed ID: 6601061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
    Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
    Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
    Loosmore S; Zealey G; Cockle S; Boux H; Chong P; Yacoob R; Klein M
    Infect Immun; 1993 Jun; 61(6):2316-24. PubMed ID: 8500874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.
    Kuo J; Douglas M; Ree HK; Lindberg AA
    Infect Immun; 1995 Jul; 63(7):2706-13. PubMed ID: 7790088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.
    Lee CJ; Lock RA; Andrew PW; Mitchell TJ; Hansman D; Paton JC
    Vaccine; 1994 Aug; 12(10):875-8. PubMed ID: 7975828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.
    Fattom A; Vann WF; Szu SC; Sutton A; Li X; Bryla D; Schiffman G; Robbins JB; Schneerson R
    Infect Immun; 1988 Sep; 56(9):2292-8. PubMed ID: 3410538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).
    Alexander J; del Guercio MF; Frame B; Maewal A; Sette A; Nahm MH; Newman MJ
    Vaccine; 2004 Jun; 22(19):2362-7. PubMed ID: 15193395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.
    Lees A; Nelson BL; Mond JJ
    Vaccine; 1996 Feb; 14(3):190-8. PubMed ID: 8920699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.